News

Exhibition will run from March 31st to May 21st, 2023, at Prada Rong Zhai Scientific Conference will be held on April 20th, 2023, at Prada Rong Zhai NEW YORK, April 10, 2023 -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology...

Dr. Saef Izzy’s data shows one-month behavioral outcomes improvement in model of intracerebral hemorrhage (hemorrhagic stroke) Modulation of neuroinflammation by inducing FoxP3+ Tregs appears to have beneficial effect in intracerebral hemorrhage Tiziana actively...

Tiziana planning to advance foralumab, the only fully human anti-CD3 monoclonal antibody, into human testing for hemorrhagic stroke Data shows behavioral outcomes improvement at one month in model of intracerebral hemorrhage (hemorrhagic stroke) Modulation of...

Data shows reduction of microglia activation and improvement in behavior in rodent model of Alzheimer’s disease (AD) Modulation of neuroinflammation may be synergistic to existing treatments in AD NEW YORK, March 31, 2023 -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA)...

Tiziana Life Sciences to Proceed with Phase 2 Clinical Trial in Patients with Non-Active Secondary Progressive Multiple Sclerosis (SPMS) FDA Provides Positive Feedback on Intranasal Foralumab Program in Patients with Non-Active SPMS First Phase 2 trial employing...

New York, March 22, 2023 – Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company enabling breakthrough immunotherapies via novel routes of drug delivery, today announces that it has been notified that Gabriele Cerrone, its...

New York, March 21, 2023 – Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company enabling breakthrough immunotherapies via novel routes of drug delivery, today announces that it has been notified that Gabriele Cerrone, its...

New York, March 20, 2023 – Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company enabling breakthrough immunotherapies via novel routes of drug delivery, today announces that it has been notified that Gabriele Cerrone, its...

NEW YORK, March 17, 2023 -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announces that it has been notified that Gabriele...

Article entitled "New T Cell Antibody Treatment Improves Outcomes For Covid Patients" reviews the company's first in class foralumab, a unique Intranasal monoclonal antibody designed to treat multiple sclerosis and a range of other neurodegenerative diseases NEW YORK,...

Grant of share options NEW YORK, March 15, 2023 -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced the grant of the...

Illustrates that the immunological basis of the mechanism of action for intranasal foralumab is based on increasing production of naïve-like T cells and Tregs, while simultaneously decreasing the production of effector T cells Further, highlights how intranasal...

NEW YORK, November 1, 2023 -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced that its Chief Operating Officer and...

NEW YORK, January 4, 2023 -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced the Investigational New Drug (IND)...

The second Expanded Access patient (EA2) demonstrated additional clinical improvement in the Expanded Disability Status Scale (EDSS), a FDA recognized standard clinical outcome assessment score NEW YORK, January 3, 2023 -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA)...

London, 29 December 2022 – Tiziana Life Sciences Ltd (“Tiziana”, NASDAQ: TLSA), a biotechnology company enabling breakthrough CNS immunomodulation approaches to enhance the functionality of Treg-based therapies, today announced its interim results for the six months...

London, 29 December 2022 – Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announces that at its annual general meeting, held...

New York, December 16, 2022 - Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company enabling breakthrough CNS immunomodulation approaches to enhance the functionality of Treg-based therapies, announced today that the Company...

NEW YORK, Dec. 15, 2022 -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announces completion of the in-life portion of a...

NEW YORK, / December 14, 2022 / Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company enabling breakthrough CNS immunomodulation approaches to enhance the functionality of Treg-based therapies, announced that it has received a...

NEW YORK, December. 06, 2022 - Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company enabling breakthrough immunotherapies via novel routes of drug delivery, today announced that the 2022 Annual General Meeting of the Company...

Third-party research conducted by leading U.S. academic institutions published in a peer reviewed journal Frontiers in Immunology shows a favorable safety profile for intranasally administered foralumab and immunological activity in humans Finding supports Tiziana’s...

-Company to host conference call via webcast at 10 am ET - NEW YORK, November 10, 2022-- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug...

NEW YORK, November 04, 2022-- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced that the Company plans to host an...